STRO - ストゥロ・バイオファ―マ (Sutro Biopharma Inc.) ストゥロ・バイオファ―マ



symbol STRO
会社名 Sutro Biopharma Inc (ストゥロ・バイオファ―マ)
分野(sector) Health Care   ヘルスケア
産業(industry) Biotechnology: Biological Products (No Diagnostic Substances)  
業種 バイオテクノロジ―_メディカルリサ―チ   医療関連(Health Care)
概要 事業概要 Sutro Biopharma Inc. is a clinical stage drug discovery development and manufacturing company. The Company is focused on using its integrated cell-free protein synthesis platform XpressCF to create a variety of protein therapeutics for cancer and autoimmune disorders. It focuses to design therapeutics using potent modalities including cytokine-based immuno-oncology (I/O) therapeutics antibody-drug conjugates (ADCs) and bispecific antibodies that are directed primarily against clinically validated targets. Its product candidate includes STRO-001 and STRO-002. STRO-001 is an ADC directed against the cancer target CD74 for patients with multiple myeloma and non-Hodgkin lymphoma (NHL). STRO-002 is an ADC directed against folate receptor-alpha (FolRa) for patients with ovarian and endometrial cancers. STRO-001 and STRO-002 are designed and optimized for therapeutic index by placing linker-warheads at specific locations within the antibody using its XpressCF Platform.   ストゥロ・バイオファ―マは米国のバイオ医薬品企業。独自プラットフォ―ムであるXpressCFを介し、がん及び自己免疫疾患のためのタンパク質治療薬の新規開発・製造に焦点をあて事業を行う。主な製品候補には、多発性骨髄腫及び非ホジキンリンパ腫の治療薬STRO-001やSTRO-002のほか、卵巣がん及び子宮内膜がんの治療薬BCMA ADCがある。   Sutro Biopharma, Inc., located in South San Francisco, is a clinical-stage drug discovery, development and manufacturing company. Using precise protein engineering and rational design, Sutro is advancing next-generation oncology therapeutics.
本社所在地 310 Utah Avenue Suite 150 South San Francisco CA 84080 USA
代表者氏名 William J. Newell ウィリアム・J.・ニューエル
代表者役職名 CEO Director
電話番号 +1 650-392-8412
設立年月日 37712
市場名 NASDAQ National Market System
ipoyear 2018年
EBITDA EBITDA(百万ドル) -35.34900
終値(lastsale) 14.6
時価総額(marketcap) 0
時価総額 時価総額(百万ドル) 319.72020
売上高 売上高(百万ドル) 33.03600
企業価値(EV) 企業価値(EV)(百万ドル) 445.62320
当期純利益 当期純利益(百万ドル) -40.34900
決算概要 決算概要 BRIEF: For the six months ended 30 June 2018 Sutro Biopharma Inc revenues decreased 62% to $11.5M. Net loss increased from $2.9M to $23.6M. Revenues reflect Collaboration revenue decrease of 77% to $7M. Higher net loss reflects General and administrative increase of 16% to $8.1M (expense) Research and development increase of 4% to $26.7M (expense) Interest Expense increase from $0K to $784K (expense).



   Sutro Biopharma initiated buy at H.C. Wainwright citing ADC candidates  2021/06/18 20:48:23 Seeking Alpha
   Sutro Biopharma Inc. Shares Close the Day 11.5% Lower - Daily Wrap  2021/01/26 22:30:00 Kwhen Finance
Sutro Biopharma Inc. shares closed today 11.5% lower than it did at the end of yesterday. The stock is currently up 13.6% year-to-date, up 122.1% over the past 12 months, and up 62.3% over the past five years. Today, the Dow Jones Industrial Average fell 2.1%, and the S&P 500 fell 2.4%. Trading Activity Shares traded as high as $28.02 and as low as $21.21 this week.Shares closed 2e+1% below its 52-week high and 3e+2% above its 52-week low.Trading volume this week was 8.1% lower than the 10-day average and 8.4% lower than the 30-day average.Beta, a measure of the stocks volatility relative to the overall market stands at 1.6. Technical Indicators The Relative Strength Index (RSI) on the stock was under 30, indicating it may be underbought.MACD, a trend-following momentum indicator, indicates a downward trend.The stock closed above its Bollinger band, indicating it may be overbought. Market Comparative Performance The company's share price lags the S&P 500 Index today, beats it on a 1-year basis, and lags it on a 5-year basis The company's share price lags the Dow Jones Industrial Average today, beats it on a 1-year basis, and lags it on a 5-year basis The company share price lags the performance of its peers in the Health Care industry sector today, beats it on a 1-year basis, and lags it on a 5 year basis Per Group Comparative Performance The company's stock priceperformance year-to-date beats the peer average by 12.3% The company's stock price performance over the past 12 months beats the peer average by 2702.7% This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at Write to © 2020 Kwhen Inc.

 関連キーワード  (バイオテクノロジ―_メディカルリサ―チ 米国株 ストゥロ・バイオファ―マ STRO Sutro Biopharma Inc.)

 twitter  (公式ツイッターやCEOツイッターなど)